Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

RCT (n=10,584) reports sotagliflozin resulted in lower risk of composite of deaths from cardiovascular causes and hospitalisations for heart failure vs. placebo; 5.6 events per 100 patient-years vs. 7.5, respectively (hazard ratio, 0.74; 95% CI, 0.63 to 0.88; P<0.001).

New England Journal of Medicine